Endometrial Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 75 expanded access programs, clinical trials, and compassionate use pathways listed for Endometrial Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with endometrial cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 30 programs are currently active or recruiting, with the remaining 45 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, Merck Sharp & Dohme LLC, Dana-Farber Cancer Institute, Genmab, Karyopharm Therapeutics Inc, and others.
By recruiting status
Snapshot of where every Endometrial Cancer program currently sits in its lifecycle.
- Active / Recruiting30
- Inactive45
Top sponsors
Organisations running the most Endometrial Cancer programs in the directory.
- AstraZeneca5 programs
- Merck Sharp & Dohme LLC4 programs
- Dana-Farber Cancer Institute3 programs
- Genmab3 programs
- Karyopharm Therapeutics Inc3 programs
- M.D. Anderson Cancer Center3 programs
- Memorial Sloan Kettering Cancer Center3 programs
- Daiichi Sankyo2 programs
- 858 Therapeutics, Inc.1 program
- Aadi Bioscience, Inc.1 program
Endometrial Cancer programs (75)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 177Lu-BetaBart for Patients with Advanced or Hard-to-Treat Solid Tumors — Radiopharm Theranostics, Ltd
- Study on Investigational Therapy or Chemotherapy for Recurring Uterine Cancer — BioNTech SE
- Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
- Phase 2 Study of Mirvetuximab Soravtansine and Pembrolizumab for Endometrial Cancer — Dana-Farber Cancer Institute
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Study on AZD8205 Alone or with Other Cancer Drugs for Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Elacestrant Alone or with Abemaciclib for Endometrial Cancer — Memorial Sloan Kettering Cancer Center
- Study on Emiltatug Ledadotin (Emi-Le) for Patients with Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on Ivonescimab for Treating Endometrial and Cervical Cancers — Memorial Sloan Kettering Cancer Center
- Study on Lifileucel (Tumor-infiltrating Lymphocytes) for Adults with Advanced Endometrial Cancer — Iovance Biotherapeutics, Inc.
- Study on Lorigerlimab for Treating Advanced Solid Tumors — MacroGenics
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
- Study Comparing Sacituzumab Tirumotecan and Pembrolizumab Combination to Pembrolizumab Alone for Treating Mismatch Repair Proficient Endometrial Cancer — Merck Sharp & Dohme LLC
- Study on the Safety and Effectiveness of GSK4418959 Alone or with Other Cancer Drugs in Patients with Solid Tumors — GlaxoSmithKline
- Study on Abemaciclib and Letrozole for Treating Endometrial Cancer — Gynecologic Oncology Group
- Study on Adjuvant Therapy for Early Stage Endometrial Cancer with Specific Genetic Profiles — Canadian Cancer Trials Group
- Study on Avelumab and M1774 for Treating Endometrial Cancer with ARID1A Mutation — Panagiotis Konstantinopoulos, MD, PhD
- DESTINY-Endometrial01: Study on Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab for First-Line Treatment of HER2-Positive Endometrial Cancer — AstraZeneca
- Karyopharm Expanded Access Program for Selinexor — Karyopharm Therapeutics Inc
- Study on Letrozole and RAD001 for Advanced or Recurrent Endometrial Cancer — M.D. Anderson Cancer Center
- Phase II Study of Atezolizumab and Bevacizumab for Advanced Endometrial Cancer — University of Oklahoma
- Study Comparing Puxitatug Samrotecan to Chemotherapy in Advanced Endometrial Cancer — AstraZeneca
- Study on Radiation and Dostarlimab for Endometrial Cancer After Surgery — Memorial Sloan Kettering Cancer Center
- Study on Sapanisertib and Serabelisib with Paclitaxel and a Diet Substudy for Advanced or Recurrent Endometrial Cancer — Faeth Therapeutics
- Study on Dato-Dxd Alone and with Other Cancer Treatments for Advanced Solid Tumors (TROPION-PanTumor03) — AstraZeneca
- Study on Shortened Radiation Therapy for Endometrial Cancer — University of Chicago
- Study Comparing Trastuzumab Deruxtecan to Standard Chemotherapy for HER2-Positive Endometrial Cancer — Daiichi Sankyo
- Study on the Effectiveness and Safety of Rina-S Compared to Standard Treatments for Endometrial Cancer — Genmab
- Study on TT-10 and TT-4 as Single Agents and in Combination for Advanced Solid Tumors — Portage Biotech
- Study on BLU-222 for Advanced Solid Tumors — Blueprint Medicines Corporation
- Study on [225Ac]-FPI-1434 Injection for Patients with Advanced Solid Tumors — Fusion Pharmaceuticals Inc.
- Phase II Study of Everolimus, Letrozole, and Metformin for Advanced or Recurrent Endometrial Cancer — M.D. Anderson Cancer Center
- Study on the Safety and Effectiveness of NC410 and Pembrolizumab for Advanced Solid Tumors — NextCure, Inc.
- Study of CPI-0209 for Patients with Advanced Solid Tumors and Lymphomas — Constellation Pharmaceuticals
- Study on Giredestrant for Patients with Grade 1 Endometrial Cancer — Hoffmann-La Roche
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Targeted Treatments for Patients with Recurrent or Persistent Endometrial Cancer — Alliance Foundation Trials, LLC.
- Study on Vudalimab (XmAb20717) for Patients with Advanced Gynecologic and Genitourinary Cancers — Xencor, Inc.
- Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or REGN4018 for Ovarian and Uterine Cancer — Regeneron Pharmaceuticals
- ALPINE: Comparing Maintenance Treatments for Endometrial Cancer - Letrozole/Abemaciclib vs Pembrolizumab — Dana-Farber Cancer Institute
- Study on Cabozantinib and Dostarlimab for Recurrent Gynecologic Carcinosarcoma — University of Alabama at Birmingham
- Study on Ceralasertib Alone and Combined with Olaparib or Durvalumab for Patients with Solid Tumors — Rahul Aggarwal
- Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
- Study on EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors, Including MSI-H Tumors — Eikon Therapeutics
- Study on Mirvetuximab Soravtansine for Women with Folate Receptor-α Positive Endometrial Cancer — Alessandro Santin
- Study on How Insulin Analogues Affect Tumor Growth in Endometrial and Colon Cancer — Meir Medical Center
- Expanded Access Use of DKN-01 for Treating Advanced Solid Tumors — Leap Therapeutics, Inc.
- Study on Intravenous T3011 Alone and with Other Treatments for Advanced Solid Tumors — ImmVira Pharma Co. Ltd
- Study on Maintenance Treatment with Selinexor or Placebo After Chemotherapy in Endometrial Cancer Patients — Karyopharm Therapeutics Inc
- Study on Pembrolizumab, Lenvatinib, and IL-15 Superagonist N-803 with HER2 Targeting Vaccine for Advanced Endometrial Cancer — National Cancer Institute (NCI)
- Phase 2 Study on the Effectiveness of DKN-01 and Pembrolizumab for Advanced or Recurrent Endometrial Cancer — M.D. Anderson Cancer Center
- Study on PRO1107 for Patients with Advanced Solid Tumors — Genmab
- Proton Therapy for Post-Surgery Treatment of Gynecologic Cancer — Abramson Cancer Center at Penn Medicine
- Study on Abemaciclib and Letrozole with or without Metformin or Zotatifin for Endometrial or Low-Grade Serous Ovarian Cancer — Dana-Farber Cancer Institute
- Study on PRO1184 for Advanced Solid Tumors — Genmab
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Merck Sharp & Dohme LLC
- Study on the Safety and Effectiveness of Retifanlimab Alone or with Other Treatments for Advanced Endometrial Cancer After Platinum-based Chemotherapy — Incyte Corporation
- Study on Selinexor as Maintenance Therapy for Advanced or Recurrent Endometrial Cancer with P53 Wild-Type — Karyopharm Therapeutics Inc
- Study of AVZO-021 for Patients with Advanced Solid Tumors — Avenzo Therapeutics, Inc.
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study on Enfortumab Vedotin for Recurrent Endometrial Cancer — William Bradley
- Study on Favezelimab and Pembrolizumab for Treating Certain Solid Tumors — Merck Sharp & Dohme LLC
- Study on Navtemadlin as Maintenance Therapy for Advanced or Recurrent Endometrial Cancer — Kartos Therapeutics, Inc.
- Study of Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors — Merck Sharp & Dohme LLC
- Study Comparing Sacituzumab Govitecan to Doctor's Choice Treatment in Endometrial Cancer Patients After Chemotherapy and Immunotherapy — Gilead Sciences
- Study on TNG260 and an Anti-PD Antibody for Solid Tumors with STK11 Mutation — Tango Therapeutics, Inc.
- The EndoBARR Trial: Testing a New Combination of Drugs for Recurrent Endometrial Cancer — Medical College of Wisconsin
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach — University of Maryland, Baltimore
- Study on Tirzepatide for Women with Obesity and Early-Stage Endometrial Conditions — UNC Lineberger Comprehensive Cancer Center
- Study on Niraparib Maintenance Therapy for Uterine Serous Carcinoma — Northwell Health
- Study on Nab-Sirolimus and Letrozole for Advanced or Returning Endometrioid Endometrial Cancer — Aadi Bioscience, Inc.
- Study on Different Radiation Treatments for Early Stage Endometrial Cancer and Their Effects on Sexual Health — Kara Romano, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Endometrial Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.